\BOOKMARK [0][-]{section*.4}{Glossary}{}% 1
\BOOKMARK [0][-]{section*.6}{Acronyms}{}% 2
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 55
\BOOKMARK [1][-]{section.4.1}{Synthetic lethal genes in breast cancer}{chapter.4}% 56
\BOOKMARK [2][-]{subsection.4.1.1}{Synthetic lethal pathways in breast cancer}{section.4.1}% 57
\BOOKMARK [2][-]{subsection.4.1.2}{Expression profiles of synthetic lethal partners}{section.4.1}% 58
\BOOKMARK [3][-]{subsubsection.4.1.2.1}{Subgroup pathway analysis}{subsection.4.1.2}% 59
\BOOKMARK [1][-]{section.4.2}{Comparison of synthetic lethal gene candidates}{chapter.4}% 60
\BOOKMARK [2][-]{subsection.4.2.1}{Comparison with siRNA screen candidates}{section.4.2}% 61
\BOOKMARK [3][-]{subsubsection.4.2.1.1}{Comparison with correlation}{subsection.4.2.1}% 62
\BOOKMARK [3][-]{subsubsection.4.2.1.2}{Comparison with viability}{subsection.4.2.1}% 63
\BOOKMARK [3][-]{subsubsection.4.2.1.3}{Comparison with secondary siRNA screen candidates}{subsection.4.2.1}% 64
\BOOKMARK [3][-]{subsubsection.4.2.1.4}{Comparison of screen at pathway level}{subsection.4.2.1}% 65
\BOOKMARK [4][-]{subsubsubsection.4.2.1.4.1}{Resampling of genes for pathway enrichment}{subsubsection.4.2.1.4}% 66
\BOOKMARK [1][-]{section.4.3}{Metagene Analysis}{chapter.4}% 67
\BOOKMARK [2][-]{subsection.4.3.1}{Pathway expression}{section.4.3}% 68
\BOOKMARK [2][-]{subsection.4.3.2}{Somatic mutation}{section.4.3}% 69
\BOOKMARK [2][-]{subsection.4.3.3}{Mutation locus}{section.4.3}% 70
\BOOKMARK [2][-]{subsection.4.3.4}{Synthetic lethal metagenes}{section.4.3}% 71
\BOOKMARK [1][-]{section.4.4}{Replication in stomach cancer}{chapter.4}% 72
\BOOKMARK [2][-]{subsection.4.4.1}{Synthetic Lethal Genes and Pathways}{section.4.4}% 73
\BOOKMARK [2][-]{subsection.4.4.2}{Synthetic Lethal Expression Profiles}{section.4.4}% 74
\BOOKMARK [2][-]{subsection.4.4.3}{Comparison to Primary Screen}{section.4.4}% 75
\BOOKMARK [3][-]{subsubsection.4.4.3.1}{Resampling Analysis}{subsection.4.4.3}% 76
\BOOKMARK [2][-]{subsection.4.4.4}{Metagene Analysis}{section.4.4}% 77
\BOOKMARK [1][-]{section.4.5}{Global Synthetic Lethality}{chapter.4}% 78
\BOOKMARK [2][-]{subsection.4.5.1}{Hub Genes}{section.4.5}% 79
\BOOKMARK [2][-]{subsection.4.5.2}{Hub Pathways}{section.4.5}% 80
\BOOKMARK [1][-]{section.4.6}{Replication in cell line encyclopaedia}{chapter.4}% 81
\BOOKMARK [1][-]{section.4.7}{Discussion}{chapter.4}% 82
\BOOKMARK [2][-]{subsection.4.7.1}{Strengths of the SLIPT Methodology}{section.4.7}% 83
\BOOKMARK [2][-]{subsection.4.7.2}{Syntheic Lethal Pathways for E-cadherin}{section.4.7}% 84
\BOOKMARK [2][-]{subsection.4.7.3}{Replication and Validation}{section.4.7}% 85
\BOOKMARK [3][-]{subsubsection.4.7.3.1}{Integration with siRNA Screening}{subsection.4.7.3}% 86
\BOOKMARK [3][-]{subsubsection.4.7.3.2}{Replication across Tissues and Cell lines}{subsection.4.7.3}% 87
\BOOKMARK [1][-]{section.4.8}{Summary}{chapter.4}% 88
\BOOKMARK [0][-]{section*.42}{References}{}% 188
